硬皮症治疗市场、机会、成长动力、产业趋势分析与预测，2024-2032

2023年，全球硬皮症治疗市场估值为22亿美元，预计2024年至2032年复合年增长率为6.8%。 。全球系统性和局部硬皮症发病率的上升正在推动对有效治疗的需求。国家硬皮病基金会报告称，大约 30 万美国人患有硬皮病，其中许多病例可能未被诊断出来。认识的提高和早期诊断进一步推动了对专业治疗的需求。研究和开发方面的大量投资正在为市场成长创造机会。

整个硬皮症治疗产业根据药物类别、适应症、给药途径和地区进行分类。

市场依药物类别分为磷酸二酯酶前列环素类似物、5抑制剂（PHA）、免疫抑制剂、内皮素受体拮抗剂、钙通道阻断剂、止痛药等。 2023年，免疫抑制剂领域的收入最高，为7.816亿美元。免疫抑制剂因其在治疗系统性硬皮症方面的作用而在市场上占据主导地位。这些药物透过抑制过度活跃的免疫反应来减少发炎和纤维化。它们在控制肺纤维化和肾臟受累等严重症状方面的有效性使其在治疗中至关重要。

根据迹象，市场分为系统性硬皮症和局部硬皮症。系统性硬皮症细分市场在 2023 年的收入为 19 亿美元。它影响内臟器官并涉及广泛的纤维化，导致显着的发病率和死亡率。这推动了对全面和积极治疗策略的需求。人们越来越认识到系统性硬皮症对生活品质的影响，这刺激了对专门治疗方法的需求。此疾病需要采取多方面的方法来解决肺纤维化、胃肠道问题和肾臟受累等症状和併发症。

2023年，北美硬皮症治疗市场产生了11亿美元的收入，预计2024年至2032年复合年增长率为5.3%。正在上升专业人士和患者。该地区先进的医疗基础设施有利于早期诊断和管理，从而刺激了需求。北美强有力的监管框架和孤儿药支持政策鼓励硬皮病治疗方法的开发和批准。加上大量的研发资金，加速了创新疗法进入市场的速度。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 硬皮症盛行率增加
    • 患者意识不断提高
    • 政府的便利支持与倡议
  • 产业陷阱与挑战
    • 不良反应和安全问题
• 成长潜力分析
• 监管环境
• 管道分析
• 技术景观
• 波特的分析
• PESTEL分析
• 未来市场趋势
• 差距分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按药物类别，2021 - 2032 年

• 主要趋势
• 免疫抑制剂
• 磷酸二酯酶 5 抑制剂 - PHA
• 内皮素受体拮抗剂
• 前列环素类似物
• 钙通道阻断剂
• 止痛药
• 其他药物类别

第 6 章：市场估计与预测：按指标划分，2021 - 2032 年

• 主要趋势
• 系统性硬皮症
• 局限性硬皮症

第 7 章：市场估计与预测：按管理途径，2021 - 2032 年

• 主要趋势
• 口服
• 可注射
• 其他给药途径

第 8 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• Actelion (Johnson and Johnson)
• Akashi Therapeutics
• Astellas Pharma
• Bayer AG
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Galderma Laboratories
• Genkyotex
• Gilead Sciences
• GSK plc
• Pfizer, Inc.
• Prometic Life Sciences, Inc.
• F. Hoffmann La Roche Ltd.
• Sanofi SA
• United Therapeutics

The Global Scleroderma Therapeutics Market was valued at USD 2.2 billion in 2023 and is projected to grow at a CAGR of 6.8% from 2024 to 2032. This growth is driven by the increasing prevalence of scleroderma and rising patient awareness. The rising incidence of both systemic and localized scleroderma globally is boosting demand for effective treatments. The National Scleroderma Foundation reports that approximately 300,000 Americans are affected by scleroderma, with many cases likely undiagnosed. Increased awareness and earlier diagnosis are further driving demand for specialized treatments. Significant investments in research and development are creating opportunities for market growth.

The overall scleroderma therapeutics industry is classified based on the drug class, indication, route of administration, and region.

The market is segmented by drug class into phosphodiesterase prostacyclin analogs, 5 inhibitors (PHA), immunosuppressors, endothelin receptor antagonists, calcium channel blockers, analgesics, and others. In 2023, the immunosuppressors segment generated the highest revenue of USD 781.6 million. Immunosuppressors dominate the market due to their role in managing systemic scleroderma. These drugs reduce inflammation and fibrosis by suppressing the overactive immune response. Their effectiveness in controlling severe manifestations like lung fibrosis and renal involvement makes them essential in treatment.

By indication, the market is divided into systemic and localized scleroderma. The systemic scleroderma segment led with a revenue of USD 1.9 billion in 2023. Systemic scleroderma holds a larger market share due to its severity and complexity. It affects internal organs and involves widespread fibrosis, leading to significant morbidity and mortality. This drives demand for comprehensive and aggressive treatment strategies. The increasing recognition of systemic scleroderma's impact on quality-of-life fuels the demand for specialized therapeutics. The disease requires a multifaceted approach to address symptoms and complications like pulmonary fibrosis, gastrointestinal issues, and renal involvement.

In 2023, the North American scleroderma therapeutics market generated USD 1.1 billion in revenue and is expected to grow at a CAGR of 5.3% from 2024 to 2032. Demand in North America is rising due to the increasing prevalence of the disease and heightened awareness among healthcare professionals and patients. The region's advanced healthcare infrastructure facilitates early diagnosis and management, boosting demand. North America's strong regulatory framework and supportive policies for orphan drugs encourage the development and approval of scleroderma treatments. Combined with substantial R&D funding, this accelerates the introduction of innovative therapies into the market.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of scleroderma
    • 3.2.1.2 Rising patient awareness
    • 3.2.1.3 Facilitative government support and initiatives
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Adverse effects and safety concerns
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Technology landscape
• 3.7 Porter's analysis
• 3.8 PESTEL analysis
• 3.9 Future market trends
• 3.10 Gap analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Immunosuppressors
• 5.3 Phosphodiesterase 5 inhibitors - PHA
• 5.4 Endothelin receptor antagonists
• 5.5 Prostacyclin analogues
• 5.6 Calcium channel blockers
• 5.7 Analgesics
• 5.8 Other drug classes

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Systemic scleroderma
• 6.3 Localized scleroderma

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Injectable
• 7.4 Other routes of administrations

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Actelion (Johnson and Johnson)
• 9.2 Akashi Therapeutics
• 9.3 Astellas Pharma
• 9.4 Bayer AG
• 9.5 Boehringer Ingelheim
• 9.6 Bristol-Myers Squibb
• 9.7 Galderma Laboratories
• 9.8 Genkyotex
• 9.9 Gilead Sciences
• 9.10 GSK plc
• 9.11 Pfizer, Inc.
• 9.12 Prometic Life Sciences, Inc.
• 9.13 F. Hoffmann La Roche Ltd.
• 9.14 Sanofi SA
• 9.15 United Therapeutics